• Kripto Paralar
  • Tahmin Piyasaları
  • Haberler
  • Ajansal İşlem
  • Yazılar
  • Ligler

Kripto Paraları Ara

Trend Kripto Paralar

CoinRithm

Şirket

Tüzel Kişilik
Bees-x Limited
Şirket Numarası
13308136
Kuruluş Yeri
England and Wales
Kayıtlı Ofis
Monmouth House, High Street, Watford, England, WD17 1LN

CoinRithm, Bees-x Limited tarafından işletilen bir bilgi ve araştırma hizmetidir. Düzenlenmiş faaliyetleri yürütmek üzere Financial Conduct Authority (FCA) tarafından yetkilendirilmemiştir ve bu sitedeki hiçbir içerik finansal tavsiye değildir.

Keşfet

Kripto ParalarTahmin PiyasalarıHaberlerYazılarAgent ArenaLigler

Özellikler

Kontrol PaneliTicaret SimülasyonuAjansal İşlemPortföyİzleme ListesiAyarlar

Şirket

HakkımızdaMetodolojiSınıflar içinKullanım ŞartlarıGizlilik PolitikasıÇerez PolitikasıFeragatname

Destek

Destekle İletişimSSSGeliştirici kitiMCP belgeleri

Sosyal Medya

X (Twitter)FacebookLinkedInTelegramInstagramTikTokYouTube
© 2026 CoinRithm. Tüm hakları saklıdır.
Google Play'de edininApp Store'dan İndirin
  • Ana Sayfa
  • PiyasalarTahmin Piyasaları
  • Haberler
  • Kontrol Paneli
  1. Tahmin Piyasaları
  2. Regülasyon
  3. FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)
FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)

FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)

RegülasyonOne-OffHealth & Medicine6ay
KalshiKalshiKullanılabilirliği kontrol etKYC gerekli%2 ücret
Güncel ima edilen olasılık
Evet
Evet 0%
Piyasa kalitesi

24 / 100

Düşük kalite
24s Hacim

₺0

Likidite

₺0

Düşük likidite
Alis / Satis

67.0% / 75.0%

Spread

11.9%

Geniş spread
Piyasa verileri

3 dakika önce guncellendi

17 Haz 26 21:301 Oca 27 4:59

Trendler

Sonuç24sOlasılık
Evet
Evet
0%
Hayır
Hayır
100%

Seçilen sonuç

Yes0%

Kurallar

If the FDA's decision on Saroglitazar by Zydus Therapeutics in 2026 is a full approval or an accelerated approval, the market resolves to Yes.

Kalshi
  • This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.
  • Saroglitazar (sold under the brand name Lipaglyn in India) is an oral small-molecule drug developed by Zydus Therapeutics that is designed to simultaneously activate two molecular switches in the body — called PPAR-alpha and PPAR-gamma — which together regulate how the body handles fats and sugars.
  • Think of it like a dual-dial thermostat for metabolism: turning up both dials at once aims to reduce harmful lipid buildup and improve insulin sensitivity more effectively than nudging just one dial.
  • In the EPICS-III trial , it is being evaluated as a treatment for primary biliary cholangitis, a liver disease distinct from its original metabolic indications.

İlgili Piyasalar

Manifold Markets

Testosterone unscheduled/rescheduled more permissively in US by end of 2028?

₺53,3 B
Evet: 22.2%Manifold MarketsMANIFOLD MARKETS
Manifold Markets

Will China have more phase 3 drug trials than the United States in year X?

₺19,7 B
2026: 33%Manifold MarketsMANIFOLD MARKETS
Manifold Markets

Will estradiol be available over-the-counter in the US before 2030?

₺16,2 B
Evet: 8.2%Manifold MarketsMANIFOLD MARKETS
FDA decision: DTX401 (pariglasgene brecaparvovec) by Ultragenyx Pharmaceutical (in 2026)

FDA decision: DTX401 (pariglasgene brecaparvovec) by Ultragenyx Pharmaceutical (in 2026)

₺0
Evet: 0%KalshiKALSHI
Hantavirus pandemic in 2026?

Hantavirus pandemic in 2026?

₺2 Mn
Evet: 4%PolymarketPOLYMARKET
New pandemic in 2026?

New pandemic in 2026?

₺279,7 B
Evet: 11%PolymarketPOLYMARKET

Bu konularda aktif

BitcoinBTC$64,439.22-2.00%EthereumETH$1,748.49-2.62%SolanaSOL$72.00-2.35%DogecoinDOGE$0.086-1.57%XRPXRP$1.19-2.79%BNBBNB$601.07-0.89%

İlgili Haberler

Binance MiCA License Application Cleared by Greek Regulator, June 30 Update AwaitedBlockchain ReporterCLARITY Act faces ethics showdown as David Nage eyes July voteCrypto NewsBinance EU Access at Risk as Greek Regulator Set to Reject MiCA License BidBlockchain ReporterSolana Institute warns Senate against weakening CLARITY ActCrypto NewsSummer of crypto (regs): State of Crypto CoindeskPhilippine Central Bank Bars VASPs From Listing Privacy CoinsBlockchain Reporter

Kurallar

If the FDA's decision on Saroglitazar by Zydus Therapeutics in 2026 is a full approval or an accelerated approval, the market resolves to Yes.

Kalshi
  • This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.
  • Saroglitazar (sold under the brand name Lipaglyn in India) is an oral small-molecule drug developed by Zydus Therapeutics that is designed to simultaneously activate two molecular switches in the body — called PPAR-alpha and PPAR-gamma — which together regulate how the body handles fats and sugars.
  • Think of it like a dual-dial thermostat for metabolism: turning up both dials at once aims to reduce harmful lipid buildup and improve insulin sensitivity more effectively than nudging just one dial.
  • In the EPICS-III trial , it is being evaluated as a treatment for primary biliary cholangitis, a liver disease distinct from its original metabolic indications.